baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Coherus BioSciences Inc/ US19249H1032 /

20/05/2024 20:02:47	Chg. -0.0550	Volume	Bid20/05/2024	Ask20/05/2024	High	Low
2.0650USD	-2.59%	560,878 Turnover: 1.09 mill.	2.0600Bid Size: 3,100	2.0700Ask Size: 6,000	2.1250	2.0419

GlobeNewswire 09/05 Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 09/05 Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

GlobeNewswire 08/05 Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination ...

GlobeNewswire 07/05 Sandoz reports first quarter 2024 sales

GlobeNewswire 01/05 Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

GlobeNewswire 24/04 Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeti...

GlobeNewswire 08/04 Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual ...

GlobeNewswire 13/03 Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Bu...

GlobeNewswire 05/03 Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

GlobeNewswire 04/03 Coherus Completes Divestiture of Ophthalmology Franchise

GlobeNewswire 04/03 Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leader...

GlobeNewswire 23/02 Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire 21/02 Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery S...

GlobeNewswire 21/02 Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology

GlobeNewswire 05/02 Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

GlobeNewswire 22/01 Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All ...

GlobeNewswire 22/01 Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US m...

GlobeNewswire 18/01 Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Ant...

GlobeNewswire 03/01 Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 03/01 Wugen Strengthens Executive Leadership Team with Appointment of Keith Vendola, M.D., M.B.A. as Chief...

GlobeNewswire 02/01 Coherus Announces U.S. Launch of LOQTORZI™

GlobeNewswire 26/12/2023 Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery...

GlobeNewswire 22/12/2023 Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire 11/12/2023 Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi)...

GlobeNewswire 07/12/2023 Coherus BioSciences Announces CFO Transition Plans

Coherus BioSciences Inc/ US19249H1032 /

If you wish to receive reply to your feedback, please provide your email address.